Medicine details

ImageDexlan 30
NameDexlan 30
DosageCapsule
Generic NameDexlansoprazole
Classes Gastrointestinal Agent
Antiulcerants
Proton Pump Inhibitor (PPI)
Diseases Acidity
Errosive Esophagitis
Gastrointestinal Disease
GERD (Gastroesophageal Reflux Disease)
Heart Burn
CompanyIbn Sina Pharmaceutical Ind. Ltd.

Drug Package Details

Strength30 mg
Storage Condition
Origin CountryBangladesh
Commercial Pack50
Price per pack750.00
Cost per pack660.00
Package unit5 caps strip
Price per unit15.00
Cost per unit13.20
Discount0
Coupon
Remarks

Dexlansoprazole

Dexlansoprazole is a right-handed enantiomer of lansoprazole. Dexlansoprazole inhibits the H+/K ATPase which is involved in the secretion of hydrochloric acid, thereby reducing gastric acid production.

Dexlansoprazole is indicated for the following conditions

  • Healing of Erosive Esophagitis: Dexlansoprazole is indicated for healing of all grades of erosive esophagitis (EE) for up to eight weeks.
  • Maintenance of Healed Erosive Esophagitis: Dexlansoprazole is indicated to maintain healing of EE and relief of heartburn for up to six months.
  • Symptomatic Non-Erosive Gastroesophageal Reflux Disease: Dexlansoprazole is indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks.

Dexlansoprazole is available as capsules.

  • Healing of erosive esophagitis (EE): The recommended dosage is 60 mg once daily for up to 8 weeks
  • Maintenance of Healed EE and relief of heartburn: 30 mg once daily is the recommended dose.
  • Symptomatic Non-Erosive GERD: The recommended dosage is 30 mg once daily for 4 weeks

Commonly associated side effects include-

  • Diarrhea
  • Abdominal pain
  • Upper respiratory tract infection (Sinusitis, Pharyngitis)
  • Nausea
  • Vomiting
  • Flatulence
  • Anemia

 

  • Gastric Malignancy: Symptomatic response with Dexlansoprazole does not preclude the presence of gastric malignancy.
  • Acute Interstitial Nephritis: Acute interstitial nephritis has been observed in patients taking PPIs including lansoprazole. Acute interstitial nephritis may occur at any point during PPI therapy and is generally attributed to an idiopathic hypersensitivity
    reaction. Discontinue Dexlansoprazole if acute interstitial nephritis develops.
  • Cyanocobalamin (vitamin B12) Deficiency:  Daily treatment with any acid-suppressing medications over a long period of time (e.g., longer than 3 years) may lead to malabsorption of cyanocobalamin (vitamin B12) caused by hypo- or achlorhydria.
  • Clostridium Difficile Associated Diarrhea: PPI therapy like Dexlansoprazole may be associated with an increased risk of Clostridium difficile associated diarrhea, especially in hospitalized patients.
  • Dexlansoprazole therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer).
  • Hypomagnesemia, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months
  • Concomitant use of PPIs with methotrexate may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities.

Contraindication

Contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation. Examples of benzimidazole derived drugs include-

There is no know food or drink which can affect this medication. But if you are taking any vitamins, food supplements, or herbal products, please talk to your pharmacist/doctor.

Contraindicated in patients with-

  • Acute interstitial nephritis